PTC Therapeutics Inc
PTCT
ISIN null / Valor 2515234
PTC Therapeutics Inc
UMushroom community rating:
About company
PTC Therapeutics, Inc. (NASDAQ: PTCT), headquartered in South Plainfield, New Jersey, is a biopharmaceutical company that develops and commercializes therapies for rare and genetic disorders, with a particular focus on neuromuscular and CNS diseases. The company pursues a mix of small-molecule and gene- and RNA-targeted approaches and markets products in select international territories; its best‑known marketed agent is ataluren (Translarna), approved in some jurisdictions for nonsense‑mutation Duchenne muscular dystrophy. PTC’s business model combines internal drug discovery and clinical development with commercial operations, licensing and partnerships to advance a pipeline aimed at other inherited disorders and rare diseases while generating revenue from product sales, royalties and collaborative agreements.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
5861 M
Market cap (USD)
1,692,469
Daily traded volume (Shares)
45.95 / 44.7
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
